Non-alcoholic fatty liver disease

46,227views

Non-alcoholic fatty liver disease

Gastroenterology and Metabolism

Gastroenterology and Metabolism

Abdominal pain: Clinical
Gastroesophageal reflux disease (GERD)
Gastroesophageal reflux disease (GERD): Clinical
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Esophagitis: Clinical
Esophageal disorders: Clinical
Esophageal surgical conditions: Clinical
Esophageal cancer
Acid reducing medications
Esophageal disorders: Pathology review
Gastrointestinal bleeding: Clinical
Gastrointestinal bleeding: Pathology review
Pediatric gastrointestinal bleeding: Clinical
Peptic ulcers and stomach cancer: Clinical
Zollinger-Ellison syndrome
Pancreatic neuroendocrine neoplasms
Helicobacter pylori
Peptic ulcer
Gastric cancer
Gastric motility
Malabsorption syndromes: Pathology review
Malabsorption: Clinical
Short bowel syndrome (NORD)
Celiac disease
Celiac disease: Nursing process (ADPIE)
Lactose intolerance
Small bowel ischemia and infarction
Superior mesenteric artery syndrome
Inflammatory bowel disease: Pathology review
Inflammatory bowel disease: Clinical
Diverticulosis and diverticulitis
Laxatives and cathartics
Diverticular disease: Pathology review
Elimination disorders: Clinical
Volvulus
Irritable bowel syndrome
Bowel obstruction
Antidiarrheals
Ulcerative colitis
Crohn disease
Colorectal polyps
Colorectal polyps and cancer: Pathology review
Juvenile polyposis syndrome
Familial adenomatous polyposis
Peutz-Jeghers syndrome
Colorectal cancer: Clinical
Colorectal cancer
Anal conditions: Clinical
Acute pancreatitis
Pancreatitis: Pathology review
Pancreatitis: Clinical
Chronic pancreatitis
Pancreatic cancer
Viral hepatitis
Viral hepatitis: Clinical
Hepatitis medications
Hepatitis A and Hepatitis E virus
Hepatitis B and Hepatitis D virus
Hepatitis C virus
Viral hepatitis: Pathology review
Autoimmune hepatitis
Primary biliary cholangitis
Primary sclerosing cholangitis
Jaundice: Pathology review
Alcohol-associated liver disease
Cirrhosis: Pathology review
Cirrhosis
Cirrhosis: Clinical
Portal hypertension
Wilson disease
Hemochromatosis
Hepatocellular carcinoma
Benign liver tumors
Non-alcoholic fatty liver disease
Liver anatomy and physiology
Acute cholecystitis
Chronic cholecystitis
Gallbladder disorders: Pathology review
Gallbladder disorders: Clinical
Biliary colic
Gallbladder carcinoma
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Acute intermittent porphyria
Vitamin D
Osteomalacia and rickets
Major depressive disorder with seasonal pattern
Hypercalcemia
Hypocalcemia
Parathyroid conditions and calcium imbalance: Clinical
Bone disorders: Pathology review
Osteoporosis
Iron deficiency anemia
Metabolic acidosis
Respiratory acidosis
Renal tubular acidosis: Pathology review
Metabolic and respiratory acidosis: Clinical
Acid-base disturbances: Pathology review
Metabolic alkalosis
Respiratory alkalosis
Metabolic and respiratory alkalosis: Clinical
Hypernatremia
Hypernatremia: Clinical
Hyponatremia
Hyponatremia: Clinical
Hyperkalemia
Hyperkalemia: Clinical
Hypokalemia: Clinical
Hypokalemia
Electrolyte disturbances: Pathology review
Phosphate, calcium and magnesium homeostasis
Hypomagnesemia
Diabetes mellitus
Diabetes mellitus: Clinical
Diabetes mellitus: Pathology review
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Dyslipidemias: Pathology review
Gout
Gout and pseudogout: Pathology review
Bacteroides fragilis

Transcript

Watch video only

Nonalcoholic fatty liver disease is actually a spectrum of disease, going from least to most severe—steatosis, steatohepatitis, fibrosis, and finally cirrhosis.

Nonalcoholic fatty liver disease results from fat deposition in the liver, which is unrelated to alcohol or viral causes.

Typically, it affects individuals with metabolic syndrome, which includes a combination of three of the following five diagnoses: obesity, hypertension, diabetes, hypertriglyceridemia, and hyperlipidemia.

Given how common metabolic syndrome has become, it’s not surprising that the rate of nonalcoholic fatty liver disease has also increased dramatically.

It’s a massive problem growing in lock-step with expanding waistlines, affecting about three quarters of all obese individuals, including many children.

Although the exact mechanism of nonalcoholic fatty liver disease isn’t clear, insulin resistance seems to play an important role.

Over time, insulin receptors on various tissues including the liver become less responsive to insulin, and as a result the liver goes into a mode where it increases fat storage and decreases fatty acid oxidation.

That means decreased secretion of lipids into the bloodstream, in the form of lipoproteins, and increased synthesis and uptake of free fatty acids from the blood, a process called steatosis.

Steatosis causes fat droplets to form within hepatocytes, some of which become large enough to cause the hepatocytes to swell up with fat and push the nuclei to the edge of the cell.

You can see this on a histopathology slide of the liver.

All of these white circles are large deposits of fat.

Zooming out and looking at the liver, you see widespread steatosis which makes the liver appear large, soft, yellow, and greasy.

Over time, that fat in the hepatocytes is vulnerable to degradation.

Unsaturated fatty acids, or fatty acids that have at least one double bond in their carbon chain, have hydrogen atoms that are especially vulnerable to initiators such as the reactive oxygen species like the hydroxyl radical that have an unpaired electron.

In this example the hydroxyl radical pairs with the vulnerable lipid hydrogen to make water and a fatty acid radical.

The fatty acid radical is unstable and reacts with non-radicals, including molecular oxygen and undamaged fatty acids.

This goes on until one radical species reacts with another radical species, which terminates the reaction.

This process damages lipid membranes leading to things like mitochondrial dysfunction and eventually cell death.

Cell death generates inflammation, and together the process of steatosis and inflammation is referred to as steatohepatitis.

In the absence of alcohol this is called nonalcoholic steatohepatitis or NASH.

Key Takeaways

Non-alcoholic fatty liver disease (NAFLD) is a condition in which excess fat is deposited in the liver, leading to inflammation and scarring. NAFLD is a common liver disorder that affects people who do not drink alcohol excessively. NAFLD commonly affects people with metabolic syndrome, which includes a combination of three of the following five diagnoses: obesity, hypertension, diabetes, hypertriglyceridemia, and hyperlipidemia.

Symptoms of NAFLD may be subtle or absent in the early stages of the disease. In advanced stages, symptoms may include fatigue, abdominal pain, and jaundice. NAFLD can progress to a more serious condition called non-alcoholic steatohepatitis (NASH), which can lead to liver scarring and cirrhosis. Treatment for NAFLD may involve lifestyle changes such as weight loss, regular exercise, and a healthy diet to help reduce fat in the liver and improve insulin resistance.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw Hill Professional (2019)
  5. "The Role of Intestinal Bacteria Overgrowth in Obesity-Related Nonalcoholic Fatty Liver Disease" Nutrients (2014)
  6. "Non-alcoholic fatty liver disease" BMJ (2014)